Pregnane X Receptor (PXR), encoded by the NR1I2 gene, is a ligand-activated nuclear receptor that plays a pivotal role in the body's defense against xenobiotics and endobiotics. By regulating the transcription of key phase I and phase II drug-metabolizing enzymes (such as CYP3A4) and drug transporters (such as MDR1/ABCB1), PXR is a central mediator of drug-drug interactions (DDIs). Beyond its classical role in ADME-Tox safety profiling, PXR has emerged as a therapeutic target in inflammatory bowel disease (IBD), cholestatic liver disorders, and oncology, where PXR antagonists are developed to overcome multi-drug resistance.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PXR/NR1I2 drug discovery and DDI screening. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PXR/NR1I2 Ligand Binding Domain (LBD) Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Theoretical MW confirmed. |
View PXR Products |
| Gene Delivery | PXR/NR1I2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and reporter gene assays. |
View PXR Products |
| Benchmark Ab | Anti-PXR/NR1I2 Recombinant Positive Control Antibody Sequence verified, highly specific for western blot and IP validation. |
View PXR Products |
| Validator | PXR/NR1I2 siRNA Set Target-specific knockdown verification in hepatic/intestinal cell models. |
View PXR Products |
| Related Target A | CYP3A4 Primary downstream metabolic enzyme upregulated by PXR activation; essential for DDI assays. |
View CYP3A4 Products |
| Related Target B | CAR/NR1I3 Sister nuclear receptor sharing overlapping xenobiotic ligands; critical for counter-screening selectivity. |
View NR1I3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Assessing nuclear translocation & transcriptional activity | Lentivirus Premade Particles containing full-length PXR for robust stable cell line construction. |
| Nuclear receptor family off-target screening | Homolog panel proteins (CAR, FXR, GR) strictly verified by mass spectrometry for cross-reactivity profiling. |
| Lack of Controls | Recombinant benchmark antibodies and validated positive control ligands available. |
| False Positives in Small Molecule Binding | Validated siRNA sets included for functional knockdown verification in reporter assays. |
Live PXR/NR1I2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of PXR/NR1I2 is undergoing a significant paradigm shift. Historically treated as an anti-target to be avoided during drug lead optimization due to DDI risks, PXR is now actively pursued as a druggable target. The next wave of R&D focuses on developing highly selective PXR antagonists to combat chemotherapy resistance in solid tumors and selective PXR agonists/modulators to restore mucosal barrier function in inflammatory bowel diseases (IBD).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonists | Academic Institutes, Biotech Consortia | Oncology (Chemo-resistance), IBD | Co-regulator Recruitment / TR-FRET (Need high-purity PXR-LBD protein) |
| Small Molecule Agonists | Hepatology-focused Biopharma | Cholestasis, Steatohepatitis | Gene Reporter Assays (Need PXR Lentivirus for stable cell line development) |
| High-Throughput DDI Screening | Global CROs, Large Pharma ADME Units | Preclinical Safety Profiling | Selectivity Panel Assays (Need PXR, CAR, and FXR recombinant proteins) |